Edwards Lifesciences
Edwards Lifesciences Corporation, a leader in heart valve therapies and critical care monitoring, is headquartered in the United States. Founded in 1958, the company has established itself as a pioneer in the medical technology industry, particularly in the development of innovative solutions for patients with cardiovascular diseases. With a strong presence in North America, Europe, and Asia, Edwards Lifesciences focuses on advanced heart valve replacement and repair technologies, as well as haemodynamic monitoring systems. Their flagship products, including the transcatheter aortic valve replacement (TAVR) systems, are renowned for their unique design and effectiveness, significantly improving patient outcomes. Recognised for its commitment to innovation, Edwards Lifesciences has achieved numerous accolades, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in cardiac care, enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Edwards Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Edwards Lifesciences's score of 50 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Edwards Lifesciences's reported carbon emissions
In 2024, Edwards Lifesciences reported total greenhouse gas emissions of approximately 38,075,000 kg CO2e, comprising 15,682,000 kg CO2e from Scope 1 and 22,393,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming for carbon neutrality by 2030. This includes a target to reduce absolute Scope 1 and 2 emissions by 42% from a 2021 baseline. Additionally, Edwards plans to decrease upstream Scope 3 emissions by 51.6% per USD of value added within the same timeframe. The company is actively transitioning its global electricity demand to renewable sources, employing both onsite and offsite renewable energy generation methods. These initiatives are part of a broader strategy to align with 1.5°C science-based targets, demonstrating a commitment to sustainable practices within the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 4,977,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | - | - | - | - | - | - | - | 00,000,000 |
| Scope 2 | 23,498,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | - | - | - | - | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Edwards Lifesciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
